
R. M. Perkins et al. / Open Journal of Internal Medicine 2 (2012) 1-6
6
6. ACKNOWLEDGEMENTS
The investigators thank Amanda Bengier and Ryan Kissinger for assis-
tance with data extraction and programming; Haiyan Sun for assistance
with data analysis; and Zahra Daar, Bradley Moyer, Dikran Toroser,
and Margit Rezabek for editorial assistance. Dr. Perkins has received
research funding and honoraria from American Regent. Dr. Kirchner
has received research funding from American Regent. This project was
funded by Amgen, Inc.
REFERENCES
[1] Port, F.K., Wolfe, R.A., Mauger, E.A., Berling, D.P. and
Jiang, K. (1993) Comparison of survival probabilities for
dialysis patients vs cadaveric renal transplant recipients.
Journal of the American Medical Association, 270, 1339-
1343. doi:10.1001/jama.270.11.1339
[2] Laupacis, A., Keown, P., Pus, N., Krueger, H., Ferguson,
B., Wong, C. and Muirhead, N. (1996) A study of the
quality of life and cost-utility of renal transplantation.
Kidney International, 50, 235-242.
doi:10.1038/ki.1996.307
[3] Danovitch, G.M., Cohen, D.J., Weir, M.R., Stock, P.G.,
Bennet, W.M., Christensen, L.L. and Sung, R.S. (2005)
Current status of kidney and pancreas transplantation in
the United States, 1994-2003. American Journal of Trans-
plantati on, 5, 904-915.
doi:10.1111/j.1600-6135.2005.00835.x
[4] Meier-Kriesche, H.U. and Kaplan, B. (2002) Waiting
time on dialysis as the strongest modifiable risk factor for
renal transplant outcomes: A paired donor kidney analy-
sis. Transplantation, 74, 1377-1381.
doi:10.1097/00007890-200211270-00005
[5] Mange, K.C., Joffe, M.M. and Feldman, H.I. (2001) Ef-
fect of the use or nonuse of long-term dialysis on the
subsequent survival of renal transplants from living do-
nors. The New England Journal of Medicine, 344, 726-
731. doi:10.1056/NEJM200103083441004
[6] Sanfilippo, F.P., Vaughn, W.K., Peters, T.G., Shield, C.F.
3rd, Adams, P.L., Lorber, M.I. and Williams, G.M. (1992)
Factors affecting the waiting time of cadaveric kidney
transplant candidates in the United States. Journal of the
American Medical Association, 267, 247-252.
doi:10.1001/jama.1992.03480020057031
[7] Wolfe, R.A., Ashby, V.B., Milford, E.L., Bloembergen,
W.E., Agodoa, L.Y.C., Held, P.J. and Port, F.K. (2000)
Differences in access to cadaveric renal transplantation in
the United States. American Journal of Kidney Diseases,
36, 1025-1033. doi:10.1053/ajkd.2000.19106
[8] Vella, J.P., O’Neill, D., Atkins, N., Donohoe, J.F. and
Walshe, J.J. (1998) Sensitization to human leukocyte an-
tigen before and after the introduction of erythropoietin.
Nephrology Dialysis Transplantation, 13, 2027-2032.
doi:10.1093/ndt/13.8.2027
[9] Ibrahim, H.N., Ishani, A., Foley, R.N., Guo, H., Liu, J.
and Collins, A.J. (2008) Temporal trends in red blood
transfusion among US dialysis patients, 1992-2005. Am-
erican Journal of Kidney Diseases, 52, 1115-1121.
doi:10.1053/j.ajkd.2008.07.022
[10] Lawler, E.V., Bradbury, B.D., Fonda, J.R., Gaziano, J.M.
and Gagnon, D.R. (2010) Transfusion burden among pa-
tients with chronic kidney disease and anemia. Clinical
Journal of the American Society of Nephrology, 5, 667-
672. doi:10.2215/CJN.06020809
[11] Wu, J., Roy, J. and Stewart, W.F. (2010) Prediction mod-
eling using EHR data: Challenges, strategies, and a com-
parison of machine learning approaches. Medical Care,
48, 106-113. doi:10.1097/MLR.0b013e3181de9e17
[12] Charlson, M.E., Pompei, P., Ales, K.L. and MacKenzie,
C.R. (1987) A new method of classifying prognostic co-
morbidity in longitudinal studies: Development and vali-
dation. Journal of Chronic Diseases, 40, 373-383.
doi:10.1016/0021-9681(87)90171-8
[13] Van Es, A.A. and Balner, H. (1979) Effect of pretrans-
plant transfusions on kidney allograft survival. Trans-
plantation Proceedings, 11, 127-137.
[14] Lundgren, G., Groth, C.G., Albrechtsen, D., Brynger, H.,
Flatmark, A., Frödin, L., Gäbel, H., Husberg, B., Klint-
malm, G. and Maurer, W. (1986) HLA-matching and pre-
transplant blood transfusions in cadaveric renal trans-
plantation—A changing picture with cyclosporin. Lancet,
2, 66-69. doi:10.1016/S0140-6736(86)91608-9
[15] Sanfilippo, F., Vaughn, W.K., Bollinger, R.R. and Spees,
E.K. (1982) Comparative effects of pregnancy, transfu-
sion, and prior graft rejection on sensitization and renal
transplant results. Transplantation, 34, 360-366.
doi:10.1097/00007890-198212000-00010
[16] Kristal, B., Shurtz-Swirski, R., Shasha, S.M., Manaster, J.,
Shapiro, G., Furmanov, M., Hassan, K., Weissman, I. and
Sela, S. (1999) Interaction between erythropoietin and
peripheral polymorphonuclear leukocytes in hemodialysis
patients. Nephron, 81, 406-413.
doi:10.1159/000045324
[17] Strunk, T., Hartel, C., Temming, P., Matzke, N., Zimmer,
J. and Schultz, C. (2008) Erythropoietin inhibits cytokine
production of neonatal and adult leukocytes. Acta Paedi-
atrica, 97, 16-20. doi:10.1111/j.1651-2227.2007.00560.x
[18] Grimm, P.C., Sinai-Trieman, L., Sekiya, N.M., Robertson,
L.S., Robinson, B.J., Fine, R.N. and Ettenger, R.B. (1990)
Effects of recombinant human erythropoietin on HLA
sensitization and cell mediated immunity. Kidney Inter-
national, 38, 12-18. doi:10.1038/ki.1990.161
[19] Koskimies, S., Lautenschlager, I., Gronhagen-Riska, C.
and Hayry, P. (1990) Erythropoietin therapy and the an-
tibody levels of highly sensitized patients awaiting kidney
transplantation. Transplantation, 50, 707-709.
doi:10.1097/00007890-199010000-00035
[20] Grimm, P.C., Sekiya, N.M., Robertson, L.S., Robinson,
B.J. and Ettenger, R.B. (1991) Recombinant human ery-
thropoietin decreases anti-HLA sensitization and may
improve renal allograft outcome: Involvement of anti-
idiotypic antibody. Transplantation Proceedings, 23, 407-
408.
Copyright © 2012 SciRes. OPEN ACCESS